Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible
- PMID: 22123723
- PMCID: PMC4244710
- DOI: 10.1097/PGP.0b013e3182230d00
Pathologic scoring of PTEN immunohistochemistry in endometrial carcinoma is highly reproducible
Abstract
Endometrial carcinomas show frequent PTEN-PI3K pathway abnormalities, and there are currently multiple trials focused on PI3K pathway inhibitors in patients with endometrial carcinoma. PTEN immunohistochemistry may help to select patients with potential for response to targeted therapy, making it important to develop and validate this stain in formalin-fixed, paraffin-embedded tissue. Immunohistochemistry for PTEN was performed and scored independently on 118 cases of endometrial carcinomas from 2 cancer centers using monoclonal DAKO 6H2.1 antibody. Cases were scored as positive, negative, or heterogeneous; reproducibility of PTEN staining and interpretation was assessed. Overall interobserver agreement was good (weighted κ=0.80), with 82% concordance, similar for nonendometrioid (81%) and endometrioid carcinomas (85%). Twenty-one of 118 cases showed discrepant results (17%) that resulted from differences in interpretation and not staining. Our study shows that evaluation of PTEN loss by immunohistochemistry is highly reproducible with the application of standard immunohistochemical techniques and simple scoring criteria.
Figures





Similar articles
-
Expression of PTEN in endometrial liquid-based cytology.Acta Cytol. 2014;58(5):495-500. doi: 10.1159/000367961. Epub 2014 Oct 25. Acta Cytol. 2014. PMID: 25358681
-
A robust immunohistochemical assay for detecting PTEN expression in human tumors.Appl Immunohistochem Mol Morphol. 2011 Mar;19(2):173-83. doi: 10.1097/PAI.0b013e3181f1da13. Appl Immunohistochem Mol Morphol. 2011. PMID: 20930614
-
Immunohistochemistry and Next-generation Sequencing Are Complementary Tests in Identifying PTEN Abnormality in Endometrial Carcinoma Biopsies.Int J Gynecol Pathol. 2022 Jan 1;41(1):12-19. doi: 10.1097/PGP.0000000000000763. Int J Gynecol Pathol. 2022. PMID: 33720084
-
Loss of PTEN expression as diagnostic marker of endometrial precancer: A systematic review and meta-analysis.Acta Obstet Gynecol Scand. 2019 Mar;98(3):275-286. doi: 10.1111/aogs.13513. Epub 2019 Jan 6. Acta Obstet Gynecol Scand. 2019. PMID: 30511743
-
High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations.Int J Gynecol Pathol. 2019 Jan;38 Suppl 1(Iss 1 Suppl 1):S40-S63. doi: 10.1097/PGP.0000000000000491. Int J Gynecol Pathol. 2019. PMID: 30550483 Free PMC article. Review.
Cited by
-
ARNTL inhibits the malignant behaviors of oral cancer by regulating autophagy in an AKT/mTOR pathway-dependent manner.Cancer Sci. 2023 Oct;114(10):3914-3923. doi: 10.1111/cas.15928. Epub 2023 Aug 10. Cancer Sci. 2023. PMID: 37562810 Free PMC article.
-
Endometrial Carcinomas with a "Serous" Component in Young Women Are Enriched for DNA Mismatch Repair Deficiency, Lynch Syndrome, and POLE Exonuclease Domain Mutations.Am J Surg Pathol. 2020 May;44(5):641-648. doi: 10.1097/PAS.0000000000001461. Am J Surg Pathol. 2020. PMID: 32205482 Free PMC article.
-
Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing.Mod Pathol. 2012 May;25(5):699-708. doi: 10.1038/modpathol.2011.208. Epub 2012 Feb 3. Mod Pathol. 2012. PMID: 22301702 Free PMC article.
-
Mismatch repair deficiency and aberrations in the Notch and Hedgehog pathways are of prognostic value in patients with endometrial cancer.PLoS One. 2018 Dec 6;13(12):e0208221. doi: 10.1371/journal.pone.0208221. eCollection 2018. PLoS One. 2018. PMID: 30521558 Free PMC article.
-
Hereditary Syndromes Manifesting as Endometrial Carcinoma: How Can Pathological Features Aid Risk Assessment?Biomed Res Int. 2015;2015:219012. doi: 10.1155/2015/219012. Epub 2015 Jun 16. Biomed Res Int. 2015. PMID: 26161390 Free PMC article. Review.
References
-
- Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983;15(1):10–17. - PubMed
-
- Oda K, Stokoe D, Taketani Y, et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res. 2005;65:10669–10673. - PubMed
-
- Velasco A, Bussaglia E, Pallares J, et al. PIK3CA gene mutations in endometrial carcinoma. Correlation with PTEN and K-RAS alterations. Hum Pathol. 2006;37:1465–1472. - PubMed
-
- Catasus L, Gallardo A, Cuatrecasas M, et al. Concomitant PI3K-AKT and p53 alterations in endometrial carcinomas are associated with poor prognosis. Mod Pathol. 2009;22:522–529. - PubMed
-
- Engelman JA. Targeting PI3K signaling in cancer: opportunities, challenges and limitations. Nature reviews. 2009;9:550–562. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials